Chrysalis BioTherapeutics

Galveston, United States· Est. 2012

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Chrysalis BioTherapeutics is a privately held, clinical-stage biotech focused on developing regenerative peptide therapeutics that mimic the body's natural repair signals. Founded in 2012 and based in Galveston, Texas, the company has leveraged over $30 million in non-dilutive funding from NIH and BARDA to build a diverse pipeline targeting acute respiratory distress syndrome (ARDS) and radiation exposure. Its unique business model reduces investor risk by using government grants for technology validation and key development programs, while pursuing investment for clinical trials in ARDS and other indications.

Respiratory DisordersRadiology/OncologyCritical CareBiodefense

Technology Platform

The TP508 peptide platform utilizes a natural 23-amino acid sequence from human thrombin that is released after injury to initiate tissue repair by restoring vascular function, modulating inflammation, and activating endogenous stem cells.

Opportunities

The primary growth opportunities are addressing the vast unmet need in ARDS (a multi-billion dollar potential market with no approved drugs) and securing a U.S.

government procurement contract for the nuclear countermeasure, which could provide stable, non-dilutive revenue.

The regenerative platform also offers potential for expansion into other acute injury and inflammatory conditions.

Risk Factors

Key risks include clinical trial failure for systemic TP508 in ARDS, regulatory challenges under the Animal Rule for the radiation program, future dilution from equity fundraising, and dependence on government funding and procurement decisions for the countermeasure's commercial success.

Competitive Landscape

In ARDS, Chrysalis faces a field of historical failures but differentiates with TP508's multi-target mechanism acting on vascular repair and inflammation. In radiation countermeasures, competitors include other BARDA-funded agents like G-CSFs; TP508's regenerative action and post-exposure treatment window are key differentiators.